# Cobenfy for Treatment of Schizophrenia Now Approved in China **URL:** \ **Category:** News on schizophrenia and mental health matters\ **Created:** [February 8, 2026, 5:17am UTC](https://schizophreniasupport.discourse.group/t/cobenfy-for-treatment-of-schizophrenia-now-approved-in-china/2648 "2026-02-08T05:17:41Z")\ **Posts on this page:** 2\ **Page:** 1
**Author:** ![Nirvana](https://yyz2.discourse-cdn.com/flex012/user_avatar/schizophreniasupport.discourse.group/nirvana/32/615_2.png) [@Nirvana](https://schizophreniasupport.discourse.group/u/Nirvana)\ **Post date:** [February 8, 2026, 5:17am UTC](https://schizophreniasupport.discourse.group/t/cobenfy-for-treatment-of-schizophrenia-now-approved-in-china/2648/1 "2026-02-08T05:17:41Z")
# > **[Cobenfy for Treatment of Schizophrenia Now Approved in China | Psychiatric Times](https://www.psychiatrictimes.com/view/cobenfy-for-treatment-of-schizophrenia-now-approved-in-china)** > > Cobenfy gains NMPA approval in China, offering a groundbreaking treatment for schizophrenia with a unique mechanism and improved symptom management. “Cobenfy represents the first truly new therapeutic approach for schizophrenia in decades,” noted Gang Wang, MD, dean of Beijing Anding Hospital, Capital Medical University and the leading principal investigator for the Phase 3 China study.1 _ **Wang highlighted that “Cobenfy has demonstrated comprehensive improvement across positive, negative and cognitive symptoms** _, while avoiding many of the adverse effects commonly associated with traditional antipsychotics, including weight gain, hyperprolactinemia, and a problematic movement disorder called extrapyramidal symptoms, offering a meaningful new option for patients.” ---
**Author:** ![SzSupportAdmin](https://yyz2.discourse-cdn.com/flex012/user_avatar/schizophreniasupport.discourse.group/szsupportadmin/32/334_2.png) [@SzSupportAdmin](https://schizophreniasupport.discourse.group/u/SzSupportAdmin)\ **Post date:** [March 5, 2026, 5:10am UTC](https://schizophreniasupport.discourse.group/t/cobenfy-for-treatment-of-schizophrenia-now-approved-in-china/2648/2 "2026-03-05T05:10:21Z")